Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Glioblastoma (GBM), the most common malignant brain tumor, remains difficult to treat because cancer stem cells (CSCs) drive resistance and recurrence. Although the Bruton tyrosine kinase (BTK) ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Zacks Investment Research on MSN
CRSP stock rises on encouraging early data from Zugo-Cel studies
Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing ...
Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of ...
A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback